Viewing StudyNCT06109779



Ignite Creation Date: 2024-05-06 @ 7:42 PM
Last Modification Date: 2024-10-26 @ 3:12 PM
Study NCT ID: NCT06109779
Status: RECRUITING
Last Update Posted: 2024-06-20
First Post: 2023-10-26

Brief Title: Rilvegostomig Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection ARTEMIDE-Biliary01
Sponsor: AstraZeneca
Organization: AstraZeneca

Conditions & Keywords Data

Conditions:
Name
Biliary Tract Cancer
Keywords:
Name View
Capecitabine View
Adenocarcinoma of the biliary tract View
Biliary tract Cancer View
Gall bladder cancer View
Intrahepatic Cholangiocarcinoma View
Distal Cholangiocarcinoma View
Perihilar Cholangiocarcinoma View
Klatskin Tumors View
Bile duct cancer View
Immunotherapy View
Cholangiocarcinoma View
Rilvegostomig View
S-1 View
Gemcitabinecisplatin View